Yabao Pharmaceutical: Terminates SY-009 Clinical Trial and Makes Provision for Impairment, Will Reduce Total Profit for 2025 by 55.79 million yuan.

Yabao Pharmaceutical announced that the company has decided to terminate the clinical research and development work of SY-009 and to fully provision for asset impairment in accordance with accounting standards. SY-009 is a sodium-glucose co-transporter 1 inhibitor intended for the treatment of type 2 diabetes patients. As of the announcement date, a total of 87.8698 million yuan has been invested in the research and development of SY-009, with 32.0765 million yuan in expenses and 55.7933 million yuan in capitalization. The provision for asset impairment in this announcement will reduce the company's total profit for the year 2025 by 55.7933 million yuan.